Brief: Sosei Group Corp -Sosei Heptares' Partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects Of Nbi-1117570 In Healthy Adults
12/09/2023 24:02
Sept 12 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI GROUP CORP: SOSEI HEPTARES' PARTNER NEUROCRINE
BIOSCIENCES
INITIATES PHASE 1 CLINICAL STUDY EVALUATING EFFECTS OF
NBI-1117570 IN HEALTHY ADULTS
Source text for Eikon: ID:nTSuk86ffd
Further company coverage: 4565.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up